Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

–  First FDA Breakthrough Therapy Designation granted for AdenoVerse immunotherapy platform; designation prioritizes PRGN-2012 as a potential treatment for RRP ––  Designation based on positive Phase 1 clinical data that showed 50% of patients were “surgery-free” (Complete Response) after PRGN-2012 treatment with a minimum follow up of 12 months post-treatment – GERMANTOWN, Md. , June 20, … Read more

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

“We are pleased with the results of the Phase 1 study which demonstrate a favorable safety profile for PRGN-3005 UltraCAR-T. Our UltraCAR-T therapies continue to be well-tolerated with no dose limiting toxicities across our clinical stage UltraCAR-T portfolio,” said Helen Sabzevari, PhD, President and CEO of Precigen. “At this early stage, we are encouraged that … Read more

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers

–  PRGN-2009 combined with an investigational checkpoint inhibitor resulted in a 30% ORR in patients with heavily pre-treated HPV-associated cancers that were naïve or resistant to checkpoint blockade with prolonged duration of responses – –  Recurrent/metastatic HPV-associated cancers (cervical, anal, oropharyngeal, etc.) are incurable by current therapies – –  PRGN-2009 was safe and well-tolerated with only Grade … Read more